ArticleVaccines2018
Frequency of Adverse Events Following Q Fever Immunisation in Young Adults.
Article in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- A Comparison of Tests for Detecting Prior Exposure toVaccines · 2025Article
- Overview of the Q fever vaccine development: current status and future prospects.Antonie van Leeuwenhoek · 2025Review
- Molecular mechanisms ofInfection and immunity · 2024Article
- Article
- Synthetic Particulate Subunit Vaccines for the Prevention of Q Fever.Advanced healthcare materials · 2024Article
- Vaccine development: obligate intracellular bacteria new tools, old pathogens: the current state of vaccines against obligate intracellular bacteria.Frontiers in cellular and infection microbiology · 2024Review
- Unveiling promising immunogenic targets in Coxiella burnetii through in silico analysis: paving the way for novel vaccine strategies.BMC infectious diseases · 2023Article
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- Article
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- Viral and Bacterial Zoonotic Agents in Dromedary Camels from Southern Tunisia: A Seroprevalence Study.Microorganisms · 2022Article
- Murine Q Fever Vaccination Model Reveals Sex Dimorphism in Early Phase Delayed-Type Hypersensitivity Responses.Frontiers in immunology · 2022Article
- Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models ofFrontiers in immunology · 2022Article
- Preclinical Animal Models for Q Fever Vaccine Development.Frontiers in cellular and infection microbiology · 2022Review
- Immunogenicity and Reactogenicity in Q Fever Vaccine Development.Frontiers in immunology · 2022Review
- Soluble antigens derived fromCell reports. Medicine · 2021Article
- Q Fever Vaccine Development: Current Strategies and Future Considerations.Pathogens (Basel, Switzerland) · 2021Review
- Article
- The Feasibility of UsingFrontiers in immunology · 2021Article
- Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection AgainstFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Q fever is a zoonosis of concern in many countries. Vaccination is the most effective means of prevention, and since 1989, Australia has had a licensed Q fever vaccine, Q-VAX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.